Compounds and compositions as protein kinase inhibitors
View Patent ↗The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
1. A pharmaceutical composition comprising a compound
(methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
2. The pharmaceutical composition of claim 1 , comprising:
methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate.
3. The pharmaceutical composition of claim 2 , formulated for oral administration.
4. The pharmaceutical composition of claim 3 , wherein each of the one or more pharmaceutically acceptable excipients is independently selected from the group consisting of: one or more diluents, one or more lubricants, one or more binders, one or more disintegrants, one or more absorbents, one or more colorants, one or more flavors, and one or more sweeteners.
5. The pharmaceutical composition of claim 4 , wherein each of the one or more pharmaceutically acceptable excipients is independently selected from the group consisting of: lactose, dextrose, sucrose, mannitol, sorbitol, cellulose glycine, silica, talcum, stearic acid, its magnesium or calcium salt, polyethyleneglycol, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone; starches, agar, alginic acid or its sodium salt, effervescent mixtures, an absorbents, a colorant, a flavor, and a sweetener.
6. The pharmaceutical composition of claim 3 , formulated as a tablet or capsule.
7. The pharmaceutical composition of claim 2 , wherein the composition comprises from about 1 mg to about 500 mg of methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate.
8. The pharmaceutical composition of claim 1 , further comprising an additional therapeutic agent.
9. The pharmaceutical composition of claim 8 , wherein the additional therapeutic agent is an anticancer compound.
10. The pharmaceutical composition of claim 9 , wherein the anticancer compound is a MEK inhibitor.
11. The pharmaceutical composition of claim 10 , wherein the MEK inhibitor is selected from: AS703026; MSC1936369B; GSK1120212; AZD6244; PD-0325901; ARRY-438162; RDEA119; GDC0941; GDC0973; TAK-733; RO5126766; and XL-518.
12. The pharmaceutical composition of claim 11 , wherein the MEK inhibitor is ARRY-438162.
13. The pharmaceutical composition of claim 12 , comprising methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate.
14. A pharmaceutical combination comprising:
i) a compound of the formula:
methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate or a pharmaceutically acceptable salt thereof, and
ii) one or more co-agents.
15. The pharmaceutical combination of claim 14 , wherein at least one of the one or more co-agents is an anticancer compound.
16. The pharmaceutical combination of claim 15 , wherein the anticancer compound is a MEK inhibitor.
17. The pharmaceutical combination of claim 16 , wherein the MEK inhibitor is selected from: AS703026; MSC1936369B; GSK1120212; AZD6244; PD-0325901; ARRY-438162; RDEA119; GDC0941; GDC0973; TAK-733; RO5126766; and XL-518.
18. The pharmaceutical combination of claim 17 , wherein the MEK inhibitor is ARRY-438162.
19. The pharmaceutical combination of claim 18 , comprising:
methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate.
20. The pharmaceutical combination of claim 19 , wherein the combination is a non-fixed combination.
21. The pharmaceutical combination of claim 19 , wherein the combination is a fixed combination.
22. The pharmaceutical combination of claim 19 , wherein the combination comprises from about 1 mg to about 500 mg of said methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate.
23. The pharmaceutical combination of claim 14 , wherein the combination is a kit.
24. The pharmaceutical combination of claim 23 , wherein the kit further comprises instructions for administration of (i) methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate and (ii) the one or more co-agents.
25. The pharmaceutical composition of claim 1 , comprising a pharmaceutically acceptable salt of methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate.